Today's Daily Dose brings you news about BioCryst Pharma's stock offering; AxoGen and Blueprint Medicines' strong Q2 financial results; positive results of RXi Pharmaceuticals' phase I/II trial with RXI-109 for retinal scarring and reverse stock split of Synthetic Biologics.
from RTT - Biotech https://ift.tt/2McqE5N
via IFTTT
No comments:
Post a Comment